Photo by Nolan Ericson
In exploring the genetics of mitochondria—the powerhouse of the cell—Hutchinson Center researchers have made a surprising discovery that challenges previously held beliefs about the role of mutations in cancer development.
For the first time, researchers have found that the number of new mitochondrial DNA mutations is significantly lower in cancers than in normal cells.
"This is completely opposite of what we see in nuclear DNA, which has an increased overall mutation burden in cancer," said cancer geneticist Dr. Jason Bielas of the Public Health Sciences and Human Biology divisions, whose findings were published in the June 7 issue of PLoS Genetics.
Mutations are changes in the genetic sequence of a cell’s genome and can occur as a result of environmental exposure to viruses, radiation and certain chemicals, or due to spontaneous errors during cell division or DNA replication.
Mitochondria, which are primarily responsible for the cell’s energy production, are semi-autonomous; similar to the nucleus, they have their own set of DNA, which encodes genes critical for the functioning of the cell. While the role of genomic instability has been well characterized in nuclear DNA, this was the first attempt to determine whether instability in mitochondrial DNA may play a similar role in cancer growth and metastasis.
Potential for drug target
"We were surprised to find that the frequency of new mutations in mitochondrial DNA from tumor cells is decreased compared to that of normal cells," Bielas said. "By extension, this suggests, somewhat counterintuitively, that higher mitochondrial mutation rates may actually serve as a barrier to cancer development, and drugs that focus directly on increasing mitochondrial DNA damage and mutation might swap cancer’s immortality for accelerated aging and tumor-cell death."
For the study, the researchers, including first author Nolan Ericson and Dr. Mariola Kulawiec, both of the Bielas Lab, used using an ultra-sensitive test to detect mutations in mitochondrial DNA from normal and cancerous colon tissue from 20 patients prior to chemotherapy.
Bielas and colleagues first set out to analyze mutation rates in mitochondrial DNA because they wanted to see if it could act as a surrogate for nuclear DNA as a cancer biomarker. "Cells contain a thousandfold more mitochondrial genetic material than nuclear DNA, so theoretically you’d need a thousand times less tissue to get the same genetic information to predict clinical outcomes such as how fast a tumor would progress or whether it would be resistant to therapy," Bielas said.
While mitochondrial DNA proved to be an unreliable stand-in for nuclear DNA as a cancer biomarker, it offers promise as a new drug target.
"If we could increase DNA damage and mutation within the mitochondrial genome, theoretically we could decrease cancer," Bielas said. "That’s what we’re testing now. This is a whole new hypothesis."
The way mitochondria maintain genetic stability in the face of cancer, Bielas suggests, may be because unlike normal cells, cancer cells do not need oxygen to survive. In fact, cancer cells decrease the process by which they get energy from the mitochondria and rely instead on a process called glycolysis, which is a form of energy production in the absence of oxygen.
"We believe less damage occurs to mitochondrial DNA of cancer cells because they no longer need oxygen," he said. "If we could program a cancer cell to once again need oxygen, we expect it would die—with minimal side effects."
Bielas and colleagues are now testing this theory in the laboratory, seeing whether cancer cells that are reprogrammed to utilize oxygen and/or are targeted for mitochondrial DNA damage respond better to certain therapeutic agents.
"This finding is a game-changer because it challenges previous notions about the role of mutations in cancer development," said Bielas, who is also an affiliate assistant professor of pathology at the University of Washington, where the ultra-sensitive mutation-detection technology, called Random Mutation Capture, was developed. The test is so sensitive that it can detect the mutational equivalent of one misprinted letter in a library of a thousand 1,000-page books.
"This work started with the idea that there would be a huge mutation burden in the mitochondrial DNA, but our findings were completely opposite of what we had expected. Hopefully our discovery will open up new avenues for treatment, early detection and monitoring treatment response of colon cancer and other malignancies," he said.
The National Institute of Environmental Health Sciences, the Ellison Medical Foundation and Fred Hutchinson Cancer Research Center funded this research. Collaborators included researchers at the University of Washington, the University of North Carolina, and St. Vincent’s University Hospital in Dublin, Ireland.